Can CD147 work as a therapeutic target for tumors through COVID-19 infection?

Abstract

In this review, we discussed an interesting case infected with "COVID-19" (Corona Virus Disease 2019). The patients with Hodgkin's lymphoma recovered after infection with COVID-19. It may be that COVID-19 activates the patient's immune system, or it may be a coincidence. COVID-19 spike protein can interact with CD147 and use it as an entry to invade host cells. CD147 is a partner of SLC3A2, which is the chaperone subunit of cystine/glutamate reverse transporter (system XC). The catalytic subunit of system XC is SLC7A11. SLC7A11 mediated cysteine uptake plays a key role in ferroptosis. Through literature review and data analysis, we suggest that CD147, as a new potential COVID-19 infection entry, may also lead to ferroptosis of host cells. Our hypothesis is that spike protein of COVID-19 induced ferroptosis in host cells via CD147/SLC3A2/SLC7A11 complex. This is another explanation for the cancer patient recovered after COVID-19 infection.

Extracellular Vesicle-Based SARS-CoV-2 Vaccine

“…In addition to the known ACE2 receptors, binding to cell surface neuropilin receptors enhances SARS-CoV-2 infection [ 9 ]. Furthermore, the S protein of SARS-CoV-2 binds to CD147 on the cell surface, the expression of which is increased by high blood glucose levels, and subsequently enters cells, which is indicative of the poor prognosis of diabetics with COVID-19 [ 10 ]. In addition, the frequent targets of SARS-CoV-2 in humans are nerve, vascular endothelial, and epithelial cells in the respiratory and gastrointestinal tracts.…”